Radiother Oncol：放疗在乳腺癌和前列腺癌患者中的使用有上升趋势

本文旨在确定放疗的特点和其随时间变化的趋势。为未来治疗方案的设计和确定适应的治疗人群收集相关数据，并为合理应用放疗进行临床审计。来自西班牙Reina Sofia大学医院的Palacios Eito A等进行了相关研究，其结果发表在Radiother Oncol 11月的期刊上。

研究者共分析了在1998年至2008年期间9782名接受治疗的患者的数据。研究者对患者的病理结果、社会/人口学特征进行了描述。研究采用意向治疗法进行分析。研究者计算了放疗应用率并进行了比较，同时他们也统计了再次放疗率

研究结果显示，在全球范围内该时间段放疗的平均应用率为32.7%。在1998年至2008年期间，增长了23%，而该时间段内人口的增长率为1.04%，即平均增长1.13/1000人/年。在前列腺癌、乳腺癌、直肠癌和肺癌的患者中放疗分别增长了13.6倍、1.6倍和1.06倍。在接受放疗的患者中，8%需要接受同步化疗。在放疗中，以姑息性治疗为目的的治疗占了18.2%。据估计，放疗的总体利用不足率为13.4%。

在全球范围来看，研究证据显示目前放疗率还尚显不足，尤其是在肺癌患者中。但是在乳腺癌和前列腺癌患者中放疗率有上升趋势。

与放疗相关的拓展阅读：

• NEJM：西妥昔单抗方案治疗纵隔B细胞淋巴瘤可避免放疗
• Radiother Oncol：FDG-PET可评估局部晚期非小细胞肺癌同步放化疗后放疗剂量和急性食管炎的关系
• EMBO:放疗或衰老阻断神经干细胞产生神经元机制
• Circulation：放疗增加癌症患者心脏手术死亡率
• JNCI：头颅放疗剂量影响急性淋巴母细胞性白血病成人患者的认知功能 更多信息请点击：有关放疗更多资讯

Characterization and adequacy of the use of radiotherapy and its trend in time.
BACKGROUND AND PURPOSE
Characterization of radiotherapy activity and its trend over time. Gathering of parameters for future planning of our resources, applicable to similar population areas. Performing a clinical audit of appropriate use of radiotherapy.
MATERIAL AND METHODS
Analysis of 9782 patients treated between 1998 and 2008. Descriptive statistics of pathologies and social/demographic characteristics. Intention of treatment. The rate of radiotherapy utilization was estimated and compared with those considered optimal. Rate of reirradiation.
RESULTS
The average global rate of radiotherapy utilization for the period was 32.7%. It increased by 23% between 1998 and 2008, while the population of the area rose by 1.04%, equaling an average 1.13 irradiations/1000 inhabitants/year. Radiation treatment has increased by 13.6, 2.3, 1.6 and 1.06 times in patients with prostate, breast, rectal and lung cancer, respectively. Eight percent of radiotherapy treatments involve concurrent chemotherapy. The proportion of treatments with palliative intent was 18.2%. The overall underutilization of radiation therapy in our environment was an estimated 13.4%.
CONCLUSIONS
The grade of adequacy of radiation rates in relation with scientific evidence was globally considered suboptimal, especially in lung cancer. There was an upward trend of irradiation in breast and prostate cancer, tending toward rates considered optimal.